000164045 001__ 164045
000164045 005__ 20240229133511.0
000164045 0247_ $$2doi$$a10.1002/ana.25932
000164045 0247_ $$2pmid$$apmid:33068316
000164045 0247_ $$2ISSN$$a0364-5134
000164045 0247_ $$2ISSN$$a1531-8249
000164045 0247_ $$2altmetric$$aaltmetric:92595510
000164045 037__ $$aDKFZ-2020-02213
000164045 041__ $$aeng
000164045 082__ $$a610
000164045 1001_ $$00000-0001-5662-1971$$aPeters, Susan$$b0
000164045 245__ $$aBlood metal levels and amyotrophic lateral sclerosis risk: a prospective cohort.
000164045 260__ $$aHoboken, NJ$$bWiley-Blackwell$$c2021
000164045 3367_ $$2DRIVER$$aarticle
000164045 3367_ $$2DataCite$$aOutput Types/Journal article
000164045 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1614876402_3140
000164045 3367_ $$2BibTeX$$aARTICLE
000164045 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000164045 3367_ $$00$$2EndNote$$aJournal Article
000164045 500__ $$a2021 Jan;89(1):125-133
000164045 520__ $$aMetals have been suggested as risk factor for amyotrophic lateral sclerosis (ALS), but only retrospective studies are available to date. We compared metal levels in prospectively collected blood samples from ALS patients and controls, to explore whether metals are associated with ALS mortality.A nested ALS case-control study was conducted within the prospective EPIC cohort. Cases were identified through death certificates. We analyzed metal levels in erythrocyte samples obtained at recruitment, as biomarker for metal exposure from any source. Arsenic, cadmium, copper, lead, manganese, mercury, selenium and zinc concentrations were measured by inductively coupled plasma-mass spectrometry. To estimate ALS risk, we applied conditional logistic regression models.The study population comprised 107 cases (65% female) and 319 controls matched for age, sex and study center. Median time between blood collection and ALS death was 8 years (range 1-15). Comparing the highest with the lowest tertile, cadmium (odds ratio (OR) 2.04, 95% confidence interval (CI) 1.08-3.87) and lead (OR 1.89, 95%CI 0.97-3.67) concentrations suggest associations with increased ALS risk. Zinc was associated with a decreased risk (OR 0.50, 95%CI 0.27-0.94). Associations for cadmium and lead remained when limiting analyses to non-current smokers.This is the first study to compare metal levels before disease onset, minimizing reverse causation. The observed associations suggest that cadmium, lead and zinc may play a role in ALS etiology. Cadmium and lead possibly act as intermediates on the pathway from smoking to ALS. This article is protected by copyright. All rights reserved.
000164045 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000164045 588__ $$aDataset connected to CrossRef, PubMed,
000164045 7001_ $$aBroberg, Karin$$b1
000164045 7001_ $$00000-0002-1268-8629$$aGallo, Valentina$$b2
000164045 7001_ $$aLevi, Michael$$b3
000164045 7001_ $$aKippler, Maria$$b4
000164045 7001_ $$aVineis, Paolo$$b5
000164045 7001_ $$aVeldink, Jan$$b6
000164045 7001_ $$avan den Berg, Leonard$$b7
000164045 7001_ $$aMiddleton, Lefkos$$b8
000164045 7001_ $$aTravis, Ruth C$$b9
000164045 7001_ $$aBergmann, Manuela M$$b10
000164045 7001_ $$aPalli, Domenico$$b11
000164045 7001_ $$aGrioni, Sara$$b12
000164045 7001_ $$aTumino, Rosario$$b13
000164045 7001_ $$00000-0001-9724-5490$$aElbaz, Alexis$$b14
000164045 7001_ $$aVlaar, Tim$$b15
000164045 7001_ $$aMancini, Francesca$$b16
000164045 7001_ $$0P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aKühn, Tilman$$b17$$udkfz
000164045 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b18$$udkfz
000164045 7001_ $$aAgudo, Antonio$$b19
000164045 7001_ $$aGoñi, Fernando$$b20
000164045 7001_ $$aGómez, Jesús-Humberto$$b21
000164045 7001_ $$aRodríguez-Barranco, Miguel$$b22
000164045 7001_ $$00000-0001-8998-4787$$aMerino, Susana$$b23
000164045 7001_ $$aBarricarte, Aurelio$$b24
000164045 7001_ $$aTrichopoulou, Antonia$$b25
000164045 7001_ $$aJenab, Mazda$$b26
000164045 7001_ $$00000-0003-2237-0128$$aWeiderpass, Elisabete$$b27
000164045 7001_ $$aVermeulen, Roel$$b28
000164045 773__ $$0PERI:(DE-600)2037912-2$$a10.1002/ana.25932$$gp. ana.25932$$n1$$p125-133$$tAnnals of neurology$$v89$$x1531-8249$$y2021
000164045 909CO $$ooai:inrepo02.dkfz.de:164045$$pVDB
000164045 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0907a10ba1dc8f53f04907f54f6fdcfe$$aDeutsches Krebsforschungszentrum$$b17$$kDKFZ
000164045 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b18$$kDKFZ
000164045 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000164045 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000164045 9141_ $$y2021
000164045 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2020-02-26$$wger
000164045 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2020-02-26$$wger
000164045 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bANN NEUROL : 2018$$d2020-02-26
000164045 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-02-26
000164045 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-02-26
000164045 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database$$d2020-02-26
000164045 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-02-26
000164045 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2020-02-26
000164045 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index$$d2020-02-26
000164045 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-02-26
000164045 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-02-26
000164045 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-02-26
000164045 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-02-26
000164045 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2020-02-26
000164045 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-02-26
000164045 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bANN NEUROL : 2018$$d2020-02-26
000164045 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000164045 980__ $$ajournal
000164045 980__ $$aVDB
000164045 980__ $$aI:(DE-He78)C020-20160331
000164045 980__ $$aUNRESTRICTED